|
This is the essential event for companies to enable them to work effectively within the heightened scrutiny from regulatory authorities safety measures employed in clinical trials. Don’t miss the opportunity to make certain your clinical trials are meeting regulations. Join your peers as they discuss the new legislation, novel methods and technologies that monitor cardiac responses effectively, how to design development studies and clinical trials that meet safety requirements, whilst remaining cost effective
Listen to an international selection of speakers, including: - Dr Philip Sager, Executive Director, Global QT Strategy Leader & Medical Science Director, Cardiovascular Development, AstraZeneca & Clinical Professor of Medicine, UMDNJ-New Jersey School of Medicine
- Malcolm Mitchell, Director, BioPharmaceutics, Eli Lilly*
- Dr Kalyan Ghosh, Director, Clinical Biostatistics, Merck
- Dr Corina Dota, ECG Centre Manager, Medical Science Sweden, AstraZeneca
- Dr Michael Markert, Lab Head, Pharmacology, Boehringer-Ingelheim
- Dr David Goldstein, Chief, Clinical Neurocardiology Section, CNP,DIR,NINDS, National Institutes of Health (NIH)
- Dr Dhiraj Narula MD, MRCP UK, FACC, Medical Director, Quintiles ECG Services
- Dr Boaz Mendzelevski, Director, Cardiology, Cardiac Safety Services, Covance
- Dr Klaus Olejniczak, Scientific Director, Federal Institute for Drugs & Medical Devices (BfArM)
This conference will provide an excellent opportunity for you to discuss: - THE RIGHT parameters to examine in pharmacology or toxicology safety studies
- PRECLINICAL PIPELINES combating aberrant preclinical signals that negatively impact upon a safe drug
- INTEGRATING the latest technologies and protocols that aid monitoring and diagnosis
- EFFECTIVE STUDY DESIGN that lowers risk and costs
|
Events Home Page
